101 results about "Antibiotic therapy" patented technology

Class A beta-lactamase may be used for reducing side-effects in the intestine associated with antibiotic therapy with a combination of beta-lactam antibiotic and beta-lactamase inhibitor.

A convertible multi-lumen catheter that may be used for hemodialysis or other indications involving infusion and/or withdrawal of fluids from the body. Unlike existing catheters having a set number of lumens which may limit their utility as both short and long-term venous vascular devices, the catheter of the invention allows one or more additional lumens during the acute phase of catheter use with removal of these lumens (i.e. conversion) for more permanent use. A typical example of this would be a triple lumen device for hemodialysis and antibiotic therapy during an acute infection with conversion to a chronic dual lumen hemodialysis catheter after successful treatment of the infection. The lumen is permanently or semi-permanently blocked using a biocompatible plastic obturator that is inserted into the unused lumen and locked and/or glued into place.

The present invention provides for methods of preventing IBS, preventing long term irregular bowel pattern, reducing the likelihood of developing or having IBS, reducing the likelihood of developing or having long term irregular bowel pattern, mitigating IBS, mitigating long term irregular bowel pattern and reducing the likelihood of developing non-ulcer dyspepsia. The methods comprise providing an antibiotic and administering the antibiotic to a subject in need thereof.

An integrated device for diagnostic analyses used to verify the presence of bacteria in at least a biological sample mixed with a eugonic culture broth, in order to identify the type of bacteria, and to test a series of antibiotics, identifying those effective to determine the antibiotic therapy. The device comprises first examination means to verify the presence of bacteria so as to define corresponding positive biological samples and identify the type of bacteria present in the positive biological samples to define said group of antibiotics, and second examination means to verify the sensitive or resistant response of each positive biological sample to a series of antibiotics of the group of antibiotics defined by the first examination means.

A composition and method for treatment for bowel disorders is described. The composition consists of two parts. First, highly purified, insoluble, chemically unmodified fiber from plants is mixed with an aqueous solution such as water. The second component of the composition is a commercially available probiotic preparation. These commercially probiotic preparations contain large numbers of viable microorganisms of either Lactobacillus sp., Bifidobacter sp. Streptococcus sp. or yeast. Consumption of the fiber preparation or probiotic by patients with constipation secondary to surgery or chronic antibiotic therapy, ulcerative colitis or Crohn's disease results in either a resolution of the symptoms or markedly improvement in symptoms without significant side effects.

The invention relates to a primer pair, a probe and a kit for detecting the bacterium MCR-1 drug-resistant gene. The primer pair comprises an MCR-1 gene detecting upstream primer including the sequence shown by SEQ ID NO.1 and an MCR-1 gene detecting downstream primer including the sequence shown by SEQ ID NO.2. The probe for the MCR-1 gene comprises a sequence shown by SEQ ID NO.3, a fluorescence group is integrated at the 5' end, and a quenching group is integrated at the 3' end of the probe for the MCR-1 gene. The kit for detecting the bacterium MCR-1 drug-resistant gene comprises the primer pair and the probe. The primer pair, the probe and the kit for detecting the bacterium MCR-1 drug-resistant gene have the advantages of being capable of detecting the bacterium MCR-1 drug-resistant gene, good in sensitivity, high in specificity, accurate in rationing and the like. The primer pair, the probe and the kit are good for clinical detection and monitoring of the bacterium MCR-1 drug-resistant gene and guiding antibiotic therapy of patients.

Paste containing at least one monomer for radical polymerization, at least one polymer that is soluble in said at least one monomer for radical polymerization, and at least one filling agent that is poorly soluble or insoluble in said at least one monomer for radical polymerization, wherein the filling agent is a particulate inorganic filling agent possessing a BET surface of at least 40 m²/g; kit comprising pastes A and B which, when mixed, form paste C, which pastes are useful for mechanical fixation of articular endoprostheses, for covering skull defects, for filling bone cavities, for femuroplasty, for vertebroplasty, for kyphoplasty, for the manufacture of spacers or for the production of carrier materials for local antibiotics therapy, as well as a form body produced from the pastes.

The present invention relates generally to methods and materials pertaining to assays, for example immunoassays, for biomarkers in body fluids e.g. blood. The invention also relates to diagnostic or screening methods for infections, and methods of differentiating between infectious and non-infectious conditions in mammals, particularly equines, for monitoring response to anti-infective/antibiotic therapy. The invention further relates to a test fluid collection system adapted to permit dilution and analysis of the collected test fluid. The invention further relates to monitoring exertional rhabdomyolysis in equines, and assay devices for all these things.

Drug delivery systems that can deliver therapeutic and/or diagnostic agents to the colon are disclosed. The systems include pectin beads crosslinked with zinc or any divalent cation of interest, which beads are then coated with Eudragit TM -type polymers. The drug delivery systems are orally administrable, but can deliver the active agents to the colon, or, in some embodiments, to various other positions in the gastro-intestinal tract. The agents can be used to diagnose, treat, prevent, or investigate a variety of conditions, including infectious diseases, inflammatory diseases, cancers and the like. Certain agents, such as metallo-dependent enzymes, for example, ss-lactamase Ll from Stenotrophomonas maltophilia, as well as agents that inactivate macrolide, quinolone, fluoroquinolone or glycopeptide antibiotics, can reduce the quantity of residual antibiotics reaching the colon following antibiotic therapy.

The present invention relates in its broadest aspect to combined phage/antibiotic therapy. More particularly, it relates to use of (i) one or more bacteriophages and (ii) one or more antibiotics in the manufacture of a combined product for simultaneous, separate or sequential administration of (i) and (ii) to treat a bacterial infection characterized by biofilm formation, for example an infection comprising or consisting of P. aeruginosa. Treatment in this context may be either therapeutic or prophylactic treatment. Also provided are deposited bacteriophages each exhibiting different strain specificity against P. aeruginosa and combinations of such bacteriophages, e.g. a panel of six deposited bacteriophages which was found to be effective against a high percentage of clinical isolates of P. aeruginosa from canine ear infections.

The invention discloses a photosensitizer formula for photodynamically treating periodontitis and an application thereof. A hydrogel preparation for treating periodontitis takes toluidine blue as a photoactive substance and carbopol as a gel. A formula for optimizing the gel preparation comprises the following components by mass concentration: 0.05%-3% of carbopol, 0.001%-1% of toluidine blue, 0.01%-0.4% of sodium hydroxide or 0.07%-2% of triethanolamine and the balance of water. A method for photodynamically treating periodontitis, provided by the invention, can be used for replacing an antibiotic therapy, so that the problem of antibiotics abuse can be prevented; when the preparation is used for treating the oral diseases caused by infections, such as, periodontitis, the antibacterial rate of once irradiation treatment can reach up to 99.99%; serious patients can be repeatedly treated at intervals; and the photosensitizer formula is free from toxic or side effect to normal organ tissues and has wide market prospects and high application values.

The invention discloses a composite biological material for eliminating a bacterial biofilm.Ethylenediaminetetraacetic acid, lactic acid, lauryl sodium sulfate, n-nonanoic acid and glycerol monolaurate are compounded into a biofilm eliminating matrix capable of effectively eliminating the biofilm, the biofilm eliminating matrix and aloperine form the composite biological material, and the composite biological material is applied to eliminating the bacterial biofilm.The novel biofilm eliminating matrix capable of effectively eliminating the biofilm and aloperine form the composite biological material for eliminating the bacterial biofilm, the composite biological material is applied to eliminating the bacterial biofilm and has the advantages of being safe, free of resistance and environmentally friendly, through combined use, the inhibiting capacity of aloperine for the gram-positive bacterium biofilm can be enhanced, the defects of antibiotic therapy can be overcome, and the composite biological material is a novel biofilm eliminating biological material which is effective and free of resistance.

The invention relates to proteins, notably SAP-2 and SAP-3, having an antibiotic action. The invention also relates to a method for purifying certain antimicrobial proteins, as well as to a use of said antimicrobial proteins for antibiotic therapy or to a use of cells which were transfected with a DNA which codes for the proteins provided for in the invention.

The invention discloses a pharmaceutical composition for prevention and treatment of chicken gland gastritis. The pharmaceutical composition comprises the following components in parts by weight: 25-35 g of scutellaria baicalensis, 25-35 g of phellodendron amurense, 25-35 g of rhizoma sparganii, 25-35 g of rhizoma curcumae, 25-35 g of semen raphani, 25-35 g of radix aucklandiae, 25-35 g of coptis chinensis, 45-55 g of radix codonopsis, 90-110 g of radix isatidis, 25-35 g of liquorice, 25-35 g of semen armeniacae amarae, 25-35 g of rhizoma rehmanniae, 25-35 g of dried orange peel, and 25-35 g of hawthorn. Through full consideration of poultry diet characteristics, optimization design is carried out, the greatest degree of utilization of the poultry self digestive ability is beneficial for treatment effect, and thus the pharmaceutical composition not only can make up for the shortcomings of an antibiotic therapy, but also has the characteristics of rich resources, low cost and convenient use.

The invention relates to the application of naringenin in the preparation of medicine for curing pneumonia. The effect in staphylococcus aureus infection curing is proved through a rabbit erythrocyte hemolytic test, a pulmonary epithelial cell (A549) damage protection test and a mouse staphylococcus aureus pulmonary inflammation model. Compared with antibiotic therapy, naringenin therapy has the characteristics of no drug tolerance and high cure rate.

The present invention is related to compositions and methods to treat, ameliorate and/or prevent morbidity and/or mortality from microbial infections. In particular, bacterial infections that are associated with the production and release of bacterial toxins. For example, many Clostridia bacteria, such as Clostridium difficile, release toxins resulting in tissue and organ damage and death, even after antibiotic therapy that either reduces or eliminates the bacteria. In particular, various peptides, polypeptides, and proteins are disclosed herein that either inactivate Clostridium difficile toxin and/or reduce Clostridium difficile toxin production.

The pharmaceutical composition is a combination of hydrolytic lignin with moisture of 55% to 65% consisting of the particles measuring 0.15 mm to 0.55 mm, a 45% to 55% aqueous lactulose solution, and a 50% to 55% aqueous oligosaccharide solution at the following ingredient ratio (weight percent): an aqueous lactulose solution: 10÷60; oligosaccharides: 10÷50; hydrolytic lignin: quantity sufficient. Hydrolytic lignin, lactulose and fructose oligosaccharides are sequentially added and mixed using a rotor blender. The composition is administered orally for no less than 14 days and no more than 30 days, two to four times a day, depending on the patient's weight and age. The composition is used as a medicine for treatment of the gastrointestinal disorders, including bacterial, viral, protozoal enteric infections, food poisoning, acute and chronic hepatitis and cirrhosis, diarrhea, peptic ulcer, Crohn's disease, ulcerative colitis, irritable bowel syndrome, mineral disorders with Ca/Mg deficiency, including osteoporosis and other alterations of the bone formation, as an immunomodulator in atopic dermatitis and immunodeficiency conditions, for protection and recovery of intestinal flora after antibiotic therapy, chemotherapy, and radiotherapy. The result is accelerated achievement of the effect and the enhanced action on the state of intestinal microbiocenosis as well as increased effectiveness of treatment of hepatitis and liver cirrhosis, elimination of undesired adverse effects in clinical usage, and extension of indications, i.e. the extended spectrum of usage in prevention and treatment.

The invention relates to an application of bacillus subtilis in antagonism helicobacter pylori, wherein substances capable of restraining the growth of helicobacter pylori can be generated when the shake cultivation is performed on the bacillus subtilis for 9 hours at 37 DEG C and at a speed of 180 rpm (revolutions per minute) in a nutrient broth liquid culture medium, thereby efficiently restraining the growth of the helicobacter pylori; when the bacillus subtilis is cultivated for 18 hours, the antibiotic ability is maximum; and antagonistic proteins are acquired by purifying the substances, thereby preparing a preparation for treating gastrointestinal tract diseases. The invention has the following technical effects: the bacillus subtilis from probiotics has a function of maintaining the micro ecological balance of an intestinal tract; the bacillus subtilis culture has stronger antagonism to the helicobacter pylori; and compared with the antibiotic treatment method used for conventionally treating the helicobacter pylori, the bacillus subtilis can be used for overcoming the defects that the side effect by using antibiotic treatment method is strong and the symptoms are easily reappeared after the disease is treated, and the like.

Aiming at the physiological characteristics of ruminants, in order to solve the problems of digestion and inactivation of the egg yolk antibody in the rumen, the invention creatively provides two preparation modes, one is an intestinal preparation which can prevent the egg yolk antibody from passing through the rumen, and research shows that after the intestinal preparation is applied to calves, the intestinal preparation has a treatment effect on calf diarrhea caused by BEV infection, and the intestinal preparation can be used for treating the diarrhea of the calves caused by BEV infection. The effect is close to that of a traditional drug therapy, but compared with an antibiotic therapy, the method is more environment-friendly and safer; the other one is a rumen bypass preparation which can be added as a part of daily ration concentrate and is convenient to use, after the egg yolk antibody is prepared into the rumen bypass preparation, the egg yolk antibody can be prevented from being degraded in the rumen and released in the intestinal tract at a fixed point, and the treatment effect on diarrhea caused by BEV infection is achieved.

The present invention relates to agents and compositions for the modification of the growth of bacterial cells. Thus, the compounds of the present invention are useful for the prevention and/or treatment of a disease in a subject. In particular, the present invention relates to the field of repurposing pharmaceutical compounds for treatment strategies of infectious diseases, gastrointestinal disorders, inflammatory diseases, proliferative diseases, metabolic disorders, cardiovascular diseases, and immunological diseases. Some of the compounds of the present invention demonstrate high specificity in inhibiting the growth of single bacterial species. Such compounds enable narrow-spectrum antibacterial therapies, constituting a major effort of current and future drug development strategies in order to reduce side effects of antibacterial treatment plans. Particularly interesting compounds of this invention are effective against pathobiological species such as Clostridium difficile, Clostridium perfingens, Fusobacterium nucleatum, and an enterotoxigenic strain of Bacteroides fragilis. Other compounds of the present invention reveal a strong inhibitory effect on a broad spectrum of bacterial species. Such compounds are useful for broad-spectrum antibiotic therapies of infections with unknown causative infecting bacterial species. Both types of compounds, especially the ones with narrow-spectrum antibacterialactivity, can further be used for modulating the microbiome composition and targeting species associated with dysbiosis and disease.

The invention relates to a traditional Chinese medicine and especially provides a medicament for treating enteritis. The medicament is to solve a problem of side effects caused by antibiotic therapy of enteritis. The medicament is prepared from the following medicinal materials in proportion: 7-15 parts of radix bupleuri, 15-21 parts of Scutellaria baicalensis, 14-19 parts of immature bitter orange, 4-6 parts of red peony root, 3-6 parts of root of kudzu vine, 10-14 parts of carbonized sanguisorba root, 11-14 parts of rhizoma cyperi, 8-10 parts of rhizoma zingiberis, 4-6 parts of liquorice, 10-15 parts of dried orange peel, 10-13 parts of rhizoma atractylodis, 1-4 parts of coptis chinensis, 5-8 parts of scorched hawthorn fruit and 8-10 parts of schisandra chinensis. Through 2 courses of treatment, 38 cases are cured, 17 cases get better, 27 cases begin to get better and 8 cases do not get better; therefore, the total effective rate is higher than 90%..